Clinical outcomes in a contemporary series of “young” patients with castration-resistant prostate cancer who were 60 years and younger

Caffo, Orazio; Ortega, Cinzia; Lorenzo, Giuseppe Di; Sava, Teodoro; Giorgi, Ugo De; Cavaliere, Carla; Macrini, Sveva; Spizzo, Gilbert; Aieta, Michele; Messina, Caterina; Tucci, Marco; Lodde, Michele; Mansueto, Giovanni; Zucali, Paolo Andrea; Adami, Daniele; D’Angelo, Alessandro; Massari, Francesco; Morelli, Franco; Procopio, Giuseppe; Ratta, Raffaele; Fratino, Lucia; Re, Giovanni Lo; Pegoraro, M; Zustovich, Fable; Vicario, Giovanni; Ruatta, Fiorella; Federico, Piera; Russa, Francesca La; Burgio, Salvatore Luca; Maines, Francesca; Veccia, Antonello; Galligioni, Enzo

doi:10.1016/j.urolonc.2015.02.016

Cited by 6 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristics of the included studies are presented in Table 1. The publication year ranged from 1998 to 2020, and there were 38 studies 21‐58 with a total sample size of 9813 cases; 29 studies were conducted in European and American countries, and the rest were conducted in Asian countries; 37 studies described the relationship between LDH levels and overall survival (OS), 9 studies explored the association between LDH and progression‐free survival (PFS), 6 studies elaborated on castration‐sensitive prostate cancer (CSPC), and 33 studies discussed CRPC. All studies receive a scored from 6 to 8, suggesting that the studies were of moderate to high quality, and therefore, could be included.…”

Section: Resultsmentioning

confidence: 99%

Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta‐analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta‐analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the past, multiple agents have been approved for patient care in prostate cancer, many directed towards androgen-directed pathways including the androgen receptor. Abiraterone acetate (Zytiga), apalutamide (Erleada), orgovyx (Regugolix), and enzalutamide (Xtandi) are new approaches to patient care directed towards androgen inhibition (37)(38)(39)(40)(41)(42). While currently used for recurrent disease, studies are now needed to determine if these medications can function as a surrogate for traditional hormone therapy in primary management with the objective of limiting the sequelae seen with Lupron therapy.…”

Section: Combination Therapiesmentioning

confidence: 99%

“…These areas remain less well defined and are of important clinical relevance to patient care and quality of life. Radium 223, sipuleucel T immunotherapy, and more traditional chemotherapy with Docetaxol have been used in patients with advanced disease with and without hormone therapy, often with limited success due in part to previous treatments and limitations in patient normal tissue reserves (37)(38)(39)(40)(41)(42). Leutium 177 ligand is a novel radiopharmacy tool, FDA approved, which delivers beta particle radiation therapy to PSMA expressing cells and the immediate microenvironment.…”

Section: Combination Therapiesmentioning

confidence: 99%

Prostate Cancer: Advances in Radiation Oncology, Molecular Biology, and Future Treatment Strategies

et al. 2022

View full text Add to dashboard Cite

Prostate cancer remains an important health problem worldwide affecting one in every six men including members of vulnerable communities. Although successful treatments have been delivered to men affected with the disease resulting in improved patient outcome, process improvements including therapy Note to the Reader: This chapter is part of the book Urologic Cancers (ISBN: 978-0-6453320-5-6), scheduled for publication in July 2022. The book is being published by Exon Publications,

show abstract

“…Taxane-based chemotherapy (i.e., docetaxel and cabazitaxel), new generation antihormonal therapy (i.e., abiraterone acetate and enzalutamide), and, in the presence of symptomatic bone dominant disease, 223 Radium dichloride constitute the standard treatment options in all age groups [8][9][10][11][12][13]. Previous studies reported a generally less favorable outcome for patients with early-onset prostate cancer (EOPC) at the metastatic castration-resistant stage but a similar response to chemotherapeutic agents [14,15]. The overexpression of prostate-specific membrane antigen (PSMA) in prostate cancer cells is the rationale for radioligand therapy using small-molecule inhibitors with high affinity to PSMA, such as PSMA-617, commonly labelled with betaemitting 177 Lutetium (LuPSMA-RLT).…”

Section: Introductionmentioning

confidence: 99%

Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer

Mader

Groener

Tselis

et al. 2021

Cancers

View full text Add to dashboard Cite

The aim of this retrospective study was to assess the outcome of patients with metastasized castration-resistant early-onset prostate cancer refractory to chemotherapy receiving radioligand therapy with 177Lutetium-PSMA-617 (LuPSMA-RLT). Twenty-five patients of ≤55 years of age at prostate cancer diagnosis, treated with a median of four (IQR 2–6) cycles (mean of 7.7 ± 1.4 GBq per cycle) every 6–8 weeks, were analyzed. Survival outcome was calculated based on the Kaplan–Meier method. The median progression-free survival (PFS) was 3.8 months (95% CI 2.3–5.3), and overall survival (OS) was 8.5 months (95% CI 6.2–10.8). An initial PSA reduction (≥ 50%) was observed in 9/25 (36%) of patients without being significantly associated with OS (p = 0.601). PSA response (PSA decline ≥50% at 12 weeks) was observed in 12/25 (48%) of patients and significantly associated with longer OS (16.0 months, 95% CI 7.4–24.6 vs. 4.0 months, 95% CI 1.1–6.9, p = 0.002). Imaging-based response using 68Ga-PSMA-11-PET/CT after two to three cycles was seen in 11/25 (44%). Additionally, responders had a significantly longer median PFS (8.7 months, 95% CI 1.3–16.1 vs. 1.9 months, 95% CI 1.7–2.2, p < 0.001) and OS (16.0 months, 95% CI 7.6–24.4 vs. 4.0 months, 95% CI 0.9–7.1; p = 0.002). Intra- or post-therapeutic toxicity was graded according to the CTCAE v5.0 criteria. Newly developing grade ≥ 3 anemia, leukopenia, and thrombocytopenia occurred in three (12%), one (4%), and three (12%) patients, respectively. One patient showed renal toxicity (grade ≥ 3) during follow-up. Pain palliation (>2 level VAS decline) was achieved in 9/14 (64%) and performance status improvement (ECOG level decline ≥ 1) in 8/17 (47%) of patients. Compared to previous reports, radioligand therapy with 177Lu-PSMA-617 in metastasized castration-resistant early-onset prostate cancer patients refractory to chemotherapy yields similar response rates with a comparable safety profile, but is associated with shorter survival.

show abstract

Clinical outcomes in a contemporary series of “young” patients with castration-resistant prostate cancer who were 60 years and younger

Cited by 6 publications

References 30 publications

Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta‐analysis

Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta‐analysis

Prostate Cancer: Advances in Radiation Oncology, Molecular Biology, and Future Treatment Strategies

Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer

Contact Info

Product

Resources

About